RT Journal Article
T1 Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
A1 Gonzalez-Rincon, Julia
A1 Garcia-Vela, Jose A.
A1 Gomez, Sagrario
A1 Fernandez-Cuevas, Belen
A1 Nova-Gurumeta, Sara
A1 Perez-Sanz, Nuria
A1 Alcoceba, Miguel
A1 Gonzalez, Marcos
A1 Anguita, Eduardo
A1 Lopez-Jimenez, Javier
A1 Gonzalez-Barca, Eva
A1 Yanez, Lucrecia
A1 Perez-Persona, Ernesto
A1 de la Serna, Javier
A1 Fernandez-Zarzoso, Miguel
A1 Deben, Guillermo
A1 Penalver, Francisco J.
A1 Fernandez, Maria C.
A1 de Oteyza, Jaime Perez
A1 Andreu, M. angeles
A1 Ruiz-Guinaldo, M. angeles
A1 Paz-Arias, Raquel
A1 Garcia-Malo, M. Dolores
A1 Recasens, Valle
A1 Collado, Rosa
A1 Cordoba, Raul
A1 Navarro-Matilla, Belen
A1 Sanchez-Beato, Margarita
A1 Garcia-Marco, Jose A.
K1 Recurrent mutations
K1 Clinical impact
K1 Coding genome
K1 Cll
K1 Fludarabine
K1 Notch1
K1 Survival
K1 Sf3b1
K1 Tp53
K1 Cyclophosphamide
AB Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is partly reflected by the mutational status of IGHV genes. Many CLL samples have been studied in recent years by next-generation sequencing. These studies have identified recurrent somatic mutations in NOTCH1, SF3B1, ATM, TP53, BIRC3 and others genes that play roles in cell cycle, DNA repair, RNA metabolism and splicing. In this study, we have taken a deep-targeted massive sequencing approach to analyze the impact of mutations in the most frequently mutated genes in patients with CLL enrolled in the REM (rituximab en mantenimiento) clinical trial. The mutational status of our patients with CLL, except for the TP53 gene, does not seem to affect the good results obtained with maintenance therapy with rituximab after front-line FCR treatment.
PB Public library science
SN 1932-6203
YR 2021
FD 2021-01-01
LK https://hdl.handle.net/10668/25213
UL https://hdl.handle.net/10668/25213
LA en
DS RISalud
RD Apr 11, 2025